KarMMA-3: Ide-Cel vs Standard Regimens in Triple-Class–Exposed RRMM

Opinion
Video

Medical oncologists discuss recent data from KarMMA-3 investigating ide-cel CAR T-cell therapy in patients with triple-class–exposed relapsed/refractory multiple myeloma.

Related Videos
Douglas W. Sborov, MD, MS, an expert on multiple myeloma
Douglas W. Sborov, MD, MS, an expert on multiple myeloma
Related Content